Home Feedback Contents

Proton pump inhibitors
Up ACE inhibitors Adenosine Anaphylaxis Antiarrhythmics Antibacterials Anticoagulants Anti-fibrinolytics Antifungals Antiplatelet drugs Anti-virals Beta2 agonists Ca antagonists Corticosteroids Fosphenytoin Hydralazine Immunosuppressants Inotropes & vasopressors Insulin IV immunoglobulin Labetalol Mannitol Metoclopramide N-acetylcysteine Nesiritide Neuroleptic malignant syn Nitric oxide Nitroprusside Proton pump inhibitors Sedatives Serotonin syndrome Sucralfate Suxamethonium Theophylline Vasopressin

BASIC Instructor & Provider Course, October 2008, Sydney. Registration deadline 27th September.
Click here for details

Pantoprazole

Pharmacokinetics

  • adminstration: oral or IV infusion
    • bioavailability ~77%
    • absorption unaffected by food or antacids
  • elimination: completely metabolized by cytochrome P450 with metabolites excreted predominantly in urine
    • t1/2 ~1 hour
  • dosage adjustment not required in elderly and in patients with renal failure
  • t1/2  increased in patients with moderate-severe cirrhosis
  • no clinically significant drug interactions

Adverse effects

  • uncommon (<0.2% of patients)
  • diarrhoea, nausea, vomiting, flatulence
  • headache, vertigo
  • exanthema, urticaria

Further reading

Cheer SM et al. Pantoprazole. An update on its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs, 2003;63(1):101-32

©Charles Gomersall, September, 2008 unless otherwise stated. The author, editor and The Chinese University of Hong Kong take no responsibility for any adverse event resulting from the use of this webpage.
Copyright policy    Contributors